Sellas Life Sciences fell nearly 5%, snapping a five-day winning streak after surging over 330% in the past year. Investors are awaiting a key readout from the Phase 3 Regal leukemia trial. Traders are monitoring the AML summit featuring scientific advisor Guenther Koehne for potential clues. The trial has recorded 72 of the 80 survival events needed for final analysis.